Accera Presents New Pharmacogenomics Data on Medical Food Product for Alzheimer's Disease
July 15, 2009
Accera Presents New Pharmacogenomics Data on Medical Food Product for Alzheimer's Disease
Accera presented data at the International Conference on Alzheimer's Disease this week in Vienna, showing that the ketogenic compound Axona "demonstrated significant improvement" in patients who lacked the epsilon 4 variant of the APOE gene and the C/C polymorphism in IDE 7.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Takeda to Use Zinfandel's TOMM40 Test in Alzheimer's Development Program for Actos
January 12, 2011 / Pharmacogenomics Reporter - Brain Imaging, Cognitive Evaluation Link TOMM40 Alterations to Alzheimer's Risk in Healthy Patients
July 14, 2010 / Pharmacogenomics Reporter - Rodent Study Suggests Low-Dose Pioglitazone May Improve Cognitive Function in Alzheimer's Patients
July 25, 2012 / Pharmacogenomics Reporter - Genentech Takes Personalized Medicine Approach in Pursuing Amyloid Hypothesis for Alzheimer's Drug
May 23, 2012 / Pharmacogenomics Reporter - Duke University Keeping an Eye on DTC Genomics Firms that Might be Infringing its APOE Patents
April 27, 2011 / Pharmacogenomics Reporter